Literature DB >> 16434130

Protective effect of Bacillus Calmette-Guerin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina.

Elena Bonifachich1, Monica Chort, Ana Astigarraga, Nora Diaz, Beatriz Brunet, Stella Maris Pezzotto, Oscar Bottasso.   

Abstract

A hospital-based case-control study was carried out at the Vilela Children's Hospital in Rosario, Argentina, to measure the protection conferred by BCG vaccination against tuberculosis (TB). The study included 148 newly diagnosed cases of TB (75 males and 73 females, mean age 3.34+/-2.97 years, S.D.), 134 of them with pulmonary TB and 14 cases with extra-pulmonary disease. Controls (425 males and 357 females, 3.39+/-2.98 years) were selected randomly among children who attended to the Hospital showing, neither respiratory diseases nor any other infectious illnesses. Information on BCG vaccination history was assessed from scars or immunisation records. All participants were negative to human immunodeficiency virus and belonged to the lower and upper-lower socioeconomic status, being similar in place of residence and ethnic characteristics. Rate of vaccinated children was 92.6% of cases and 94.5% of controls (3.4 and 3.9% of them without scars, respectively). Regarding the total cases, the protective association between BCG and TB was statistically insignificant, as was for the pulmonary form. Among cases with extra-pulmonary disease, vaccine effectiveness attained significance [79% (95% CI=26-94)], no matter their age, sex or nutritional status. BCG vaccination exerted a beneficial role in extra-pulmonary TB, even in children not seriously undernourished.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434130     DOI: 10.1016/j.vaccine.2005.12.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

2.  The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection.

Authors:  Philana Ling Lin; Jes Dietrich; Esterlina Tan; Rodolfo M Abalos; Jasmin Burgos; Carolyn Bigbee; Matthew Bigbee; Leslie Milk; Hannah P Gideon; Mark Rodgers; Catherine Cochran; Kristi M Guinn; David R Sherman; Edwin Klein; Christopher Janssen; JoAnne L Flynn; Peter Andersen
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

3.  Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns.

Authors:  Benjamin M N Kagina; Brian Abel; Thomas J Scriba; Elizabeth J Hughes; Alana Keyser; Andreia Soares; Hoyam Gamieldien; Mzwandile Sidibana; Mark Hatherill; Sebastian Gelderbloem; Hassan Mahomed; Anthony Hawkridge; Gregory Hussey; Gilla Kaplan; Willem A Hanekom
Journal:  Am J Respir Crit Care Med       Date:  2010-06-17       Impact factor: 21.405

4.  Clinico-epidemiological profile and diagnostic procedures of pediatric tuberculosis in a tertiary care hospital of western Nepal-a case-series analysis.

Authors:  Chandrashekhar T Sreeramareddy; Narayan Ramakrishnareddy; Ravi K Shah; Ramkaji Baniya; Pradipta K Swain
Journal:  BMC Pediatr       Date:  2010-08-09       Impact factor: 2.125

5.  Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response.

Authors:  Benjamin M N Kagina; Brian Abel; Mark Bowmaker; Thomas J Scriba; Sebastian Gelderbloem; Erica Smit; Mzwandile Erasmus; Nonhlanhla Nene; Gerhard Walzl; Gillian Black; Gregory D Hussey; Anneke C Hesseling; Willem A Hanekom
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

6.  Does the BCG vaccine have different effects on strains of tuberculosis?

Authors:  A Kousha; S Farajnia; K Ansarin; M Khalili; M Shariat; L Sahebi
Journal:  Clin Exp Immunol       Date:  2020-12-01       Impact factor: 4.330

7.  A Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence.

Authors:  Carolyn M Shoen; Michelle S DeStefano; Cynthia C Hager; Kyi-Toe Tham; Miriam Braunstein; Alexandria D Allen; Hiriam O Gates; Michael H Cynamon; Douglas S Kernodle
Journal:  Vaccines (Basel)       Date:  2013-01-11

8.  Interactions between natural killer cells and dendritic cells favour T helper1-type responses to BCG in calves.

Authors:  Carly A Hamilton; Suman Mahan; Gary Entrican; Jayne C Hope
Journal:  Vet Res       Date:  2016-08-17       Impact factor: 3.683

9.  Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa.

Authors:  André G Loxton; Julia K Knaul; Leander Grode; Andrea Gutschmidt; Christiane Meller; Bernd Eisele; Hilary Johnstone; Gian van der Spuy; Jeroen Maertzdorf; Stefan H E Kaufmann; Anneke C Hesseling; Gerhard Walzl; Mark F Cotton
Journal:  Clin Vaccine Immunol       Date:  2017-02-06

10.  The epidemiology of childhood tuberculosis in the Netherlands: still room for prevention.

Authors:  Connie G M Erkens; Gerard de Vries; Sytze T Keizer; Erika Slump; Susan van den Hof
Journal:  BMC Infect Dis       Date:  2014-05-31       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.